Qvella_Logo_Tagline_2Color_RGBQvella_Logo_Tagline_2Color_RGBQvella_Logo_Tagline_2Color_RGBQvella_Logo_Tagline_2Color_RGB
  • Home
  • Sepsis
  • FAST System
  • FAST System Resources
  • FAST-ID BSI
  • News & Events
  • Leadership
  • Careers
  • Contact
  • Home
  • Sepsis
  • FAST System
  • FAST System Resources
  • FAST-ID BSI
  • News & Events
  • Leadership
  • Careers
  • Contact
✕

In print

An article emphasizing the importance of the research and development being conducted by Qvella Corporation was published in the May 22, 2012 edition of the Financial Post newspaper. Authored by Rebecca Walberg, the article highlighted the many advantages of the Qvella’s rapid diagnostic device to both the patient and their healthcare providers.

Learn More

Related posts

April 22, 2022

Qvella FAST™ System and FAST-PBC Prep™ Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use


Read more
March 21, 2022

DGHM 2022


Read more
March 21, 2022

RICAI 2022


Read more

Qvella’s Vision is to Enable Faster Clinical Decisions for Better Patient Outcomes

Last updated on March 9, 2022

QUICK LINKS

  • Home
  • Sepsis
  • FAST System
  • FAST System Resources
  • FAST-ID BSI
  • News & Events
  • Leadership
  • Careers
  • Privacy Policy
  • Terms & Conditions

GET IN TOUCH

Qvella Corporation Headquarters:
9133 Leslie Street, Unit 110
Richmond Hill, ON L4B 4N1
Canada

Tel: (833) 478-3552

Qvella Corporation USA:
2035 Corte del Nogal,  Suite 105
Carlsbad, CA 92011
United States
Tel: (833) 478-3552

Qvella Corporation Europe:
Generaal de Wittelaan 17C
2800 Mechelen
Belgium
Tel: +32 473 59 32 36

© 2022 Qvella Corporation. All Rights Reserved.